LEADER 05122nam 2200745 450 001 9910813407403321 005 20211011233323.0 010 $a0-8122-0905-2 024 7 $a10.9783/9780812209051 035 $a(CKB)3710000000083171 035 $a(SSID)ssj0001179427 035 $a(PQKBManifestationID)11764621 035 $a(PQKBTitleCode)TC0001179427 035 $a(PQKBWorkID)11181289 035 $a(PQKB)10553346 035 $a(OCoLC)875446995 035 $a(MdBmJHUP)muse32971 035 $a(DE-B1597)449805 035 $a(OCoLC)874148896 035 $a(DE-B1597)9780812209051 035 $a(Au-PeEL)EBL3442320 035 $a(CaPaEBR)ebr10827646 035 $a(CaONFJC)MIL682692 035 $a(MiAaPQ)EBC3442320 035 $a(EXLCZ)993710000000083171 100 $a20140121h20142014 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aDemocracy without justice in Spain $ethe politics of forgetting /$fOmar Guillermo Encarnacio?n 205 $a1st ed. 210 1$aPhiladelphia, Pennsylvania :$cUniversity of Pennsylvania Press,$d2014. 210 4$d©2014 215 $a1 online resource (257 pages) 225 0 $aPennsylvania Studies in Human Rights 300 $aBibliographic Level Mode of Issuance: Monograph 311 0 $a1-322-51410-0 311 0 $a0-8122-4568-7 320 $aIncludes bibliographical references and index. 327 $tFront matter --$tContents --$tIntroduction --$tChapter 1. History, Politics, and Forgetting in Spain --$tChapter 2. Regime Transition and the Rise of Forgetting, 1977?1981 --$tChapter 3. Socialist Rule and the Years of ?Disremembering,? 1982?1996 --$tChapter 4. A Silent Accomplice: Civil Society and the Persistence of Forgetting --$tChapter 5. Pinochet?s Revenge: Awakening the Memory of War and Dictatorship --$tChapter 6. Post-Transitional Justice in Zapatero?s Second Transition --$tChapter 7. Coping with the Past: Spanish Lessons --$tNotes --$tReferences --$tIndex --$tAcknowledgments 330 $aSpain is a notable exception to the implicit rules of late twentieth-century democratization: after the death of General Francisco Franco in 1975, the recovering nation began to consolidate democracy without enacting any of the mechanisms promoted by the international transitional justice movement. There were no political trials, no truth and reconciliation commissions, no formal attributions of blame, and no apologies. Instead, Spain's national parties negotiated the Pact of Forgetting, an agreement intended to place the bloody Spanish Civil War and the authoritarian excesses of the Franco dictatorship firmly in the past, not to be revisited even in conversation. Formalized by an amnesty law in 1977, this agreement defies the conventional wisdom that considers retribution and reconciliation vital to rebuilding a stable nation. Although not without its dark side, such as the silence imposed upon the victims of the Civil War and the dictatorship, the Pact of Forgetting allowed for the peaceful emergence of a democratic state, one with remarkable political stability and even a reputation as a trailblazer for the national rights and protections of minority groups.Omar G. Encarnación examines the factors in Spanish political history that made the Pact of Forgetting possible, tracing the challenges and consequences of sustaining the agreement until its dramatic reversal with the 2007 Law of Historical Memory. The combined forces of a collective will to avoid revisiting the traumas of a difficult and painful past and the reliance on the reformed political institutions of the old regime to anchor the democratic transition created a climate conducive to forgetting. At the same time, the political movement to forget encouraged the embrace of a new national identity as a modern and democratic European state. Demonstrating the surprising compatibility of forgetting and democracy, Democratization Without Justice in Spain offers a crucial counterexample to the transitional justice movement. The refusal to confront and redress the past did not inhibit the rise of a successful democracy in Spain; on the contrary, by leaving the past behind, Spain chose not to repeat it. 410 0$aPennsylvania studies in human rights. 606 $aDemocratization$zSpain 606 $aTransitional justice$zSpain 606 $aCriminal justice, Administration of$zSpain 607 $aSpain$xPolitics and government$y1975-1982 607 $aSpain$xHistory$yCivil War, 1936-1939$xInfluence 610 $aHuman Rights. 610 $aLaw. 610 $aPolitical Science. 610 $aPublic Policy. 615 0$aDemocratization 615 0$aTransitional justice 615 0$aCriminal justice, Administration of 676 $a320.946/09047 700 $aEncarnacio?n$b Omar Guillermo$f1962-$01604944 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910813407403321 996 $aDemocracy without justice in Spain$93929932 997 $aUNINA LEADER 06754nam 22005895 450 001 9911015964003321 005 20250716130243.0 010 $a3-031-90225-4 024 7 $a10.1007/978-3-031-90225-3 035 $a(MiAaPQ)EBC32218095 035 $a(Au-PeEL)EBL32218095 035 $a(CKB)39660052800041 035 $a(DE-He213)978-3-031-90225-3 035 $a(OCoLC)1528960484 035 $a(EXLCZ)9939660052800041 100 $a20250716d2025 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aControversies in Hepatocellular Carcinoma /$fedited by Nancy S. Reau, Amit G. Singal 205 $a1st ed. 2025. 210 1$aCham :$cSpringer Nature Switzerland :$cImprint: Springer,$d2025. 215 $a1 online resource (548 pages) 311 08$a3-031-90224-6 327 $aSection 1 - Risk Assessment and Chemoprevention -- Controversy 1 - Should All Patients with Hepatitis B Virus Undergo Hepatocellular Carcinoma Surveillance? -- Controversy 2 - Should Hepatocellular Carcinoma Surveillance Be Restricted to Those with Cirrhosis Among Patients With Hepatitis C? -- Controversy 3 - Should Hepatocellular Carcinoma Surveillance Be Performed in Patients with Noncirrhotic Nonalcoholic Steatohepatitis? -- Controversy 4 -Can Risk Stratification Models Be Used to Identify Patients without Cirrhosis who Might Benefit From Hepatocellular Carcinoma Surveillance? -- Controversy 5 - Should Hepatocellular Carcinoma Surveillance Be Performed Only for Patients with Decompensated Cirrhosis if They Are Listed for Liver Transplantation? -- Controversy 6 - Should Statins and Aspirin Be Used for Hepatocellular Carcinoma Chemoprevention in Patients with Cirrhosis? -- Section 2 - Liver Cancer Surveillance -- Controversy 7 - Should A Randomized Controlled Trial of Hepatocellular Carcinoma in Patients with Cirrhosis Be Performed? -- Controversy 8 - Should Contrast-Enhanced Computed Tomography and/or Magnetic Resonance Imaging Play a Routine Role in Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis? -- Controversy 9 - Should Biomarkers, Such as Alpha Fetoprotein, Play a Routine Role in Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis? -- Controversy 10 - Should Patients with Hepatitis C Virus Cirrhosis Undergo Hepatocellular Carcinoma Surveillance Indefinitely? -- Controversy 11 - Should Patients with Hepatitis C Virus Cirrhosis Undergo Hepatocellular Carcinoma Surveillance Indefinitely? -- Section 3 - Diagnosis -- Controversy 12 - Should All Liver Lesions in Patients with Cirrhosis Be Characterized and Reported Using Liver Imaging Reporting and Data System Criteria? -- Controversy 13 - Can Imaging Findings of Arterial Enhancement and Washout Still Represent a Benign Liver Lesion? -- Controversy 14 - Should Diagnostic Liver Biopsy Be Performed in Patients with Cirrhosis who Have Characteristic Imaging Features of Hepatocellular Carcinoma? -- Controversy 15 - Is Contrast-Enhanced Ultrasound Sufficiently Accurate to Be Used for Noninvasive Diagnosis of Hepatocellular Carcinoma? -- Section 4 - Prognosis -- Controversy 16 - Should Barcelona Clinic Liver Cancer Staging Be Used as the Preferred Staging System for Hepatocellular Carcinoma? -- Section 5 - TreatmentControversy 17 - Should Resection Be the Preferred Therapeutic Option for Patients Within the Milan Criteria and Compensated Cirrhosis Without Portal Hypertension? -- Controversy 18 - Should Liver Transplantation Be the Preferred Therapeutic Option in Patients with Compensated Cirrhosis and Portal Hypertension? -- Controversy 19 - Should Radiation-Based Therapy Be Considered in All Patients with Hepatocellular Carcinoma? -- Controversy 20 - Should Transarterial Radioembolization be the First-Line Therapy Compared to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma? -- Controversy 21 - Should All Patients Listed for Liver Transplantation Receive Bridging Therapy Before Transplant? -- Controversy 22 - Should Transplant Criteria Be Broadened Beyond United Network for Organ Sharing (UNOS) Downstaging Protocol to Include Larger Tumors? -- Controversy 23 - Should All Tyrosine Kinase Inhibitors Be Considered Equal for First-Line Hepatocellular Carcinoma Treatment? -- Controversy 24 - Should All Patients Be Considered for Locoregional Therapy Before Systemic Therapy? -- Controversy 25 - Should Direct-Acting Antivirals Be Given to Patients with Hepatocellular Carcinoma? -- Controversy 26 - Should Locoregional Therapy Be Given in Combination with Systemic Therapy? -- Controversy 27 - Should Patients with Decompensated Cirrhosis Receive Systemic Therapy? -- Controversy 28 - Would Effectively Downstaging Hepatocellular Carcinoma Allow All Patients to Be Considered for Liver Transplantation? -- Controversy 29 - Should Surgery Be Considered for Hepatocellular Carcinoma if Unable to Be Performed at Presentation? -- Controversy 30- Should Rapamune (Sirolimus)-Based Immunomodulation Be Given Post Transplant for Those Transplanted for or Found to Have Incidental Hepatocellular -- Controversy 31- Should Systemic Therapy Be Offered to all Patients Post Transplant for Those Transplanted for or Found to Have Incidental Hepatocellular Carcinoma? -- Controversy 32 - Should Post-Liver Transplantation Surveillance for Hepatocellular Carcinoma (HCC) Stop if There Is no HCC Recurrence After 5 Years?. 330 $aThis book is written for clinicians who care for patients with hepatocellular carcinoma (HCC) as well as health services researchers doing work in this area. The Editors and authors cover some of the emerging controversial topics that come up in HCC clinical practice and research. There are over 30 questions ranging from screening and diagnosis to therapeutics and survivorship. Chapters are begin with a controversy and the authors defend or refute the question. Comprehensive and unique, this book aims to help with management of this patient population. 606 $aOncology 606 $aLiver 606 $aPhysiology 606 $aDrug delivery systems 606 $aOncology 606 $aHepatic Physiology 606 $aDrug Delivery 615 0$aOncology. 615 0$aLiver. 615 0$aPhysiology. 615 0$aDrug delivery systems. 615 14$aOncology. 615 24$aHepatic Physiology. 615 24$aDrug Delivery. 676 $a616.994 700 $aReau$b Nancy S$01834954 701 $aSingal$b Amit G$01834955 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9911015964003321 996 $aControversies in Hepatocellular Carcinoma$94410642 997 $aUNINA